Avid Bioservices Inc (CDMO)

[entdoc]

Cloaked, you wrote; "Are you saying that AstraZeneca is going to run the Durvalumab+Bavituximab combo clinical trial, which is a immuno agent combination, in NSCLC just for the show. Because under your statement below that is all what is would be." Those are your words, not mine. AZ need sampan' that will make Durvalumab work. We'll see. I'm sure some of the AZ and PPHM scientists will learn from it. I'm not so sure we will learn or profit from it. Don't get me wrong cloaked, I am still invested here, and would love for lightening to strike, whether it is with durvalumab or another. The only way we'll know if it adds a few months of life is to try it...with a statistically more cooperative control group.